Recently, Revotek Co., Ltd. (“Revotek”), a vertically integrated biotech company specialized in 3D bioprinting, and West China Hospital of Sichuan University, a leading research hospital in China, have reached an agreement, in which the latter shall introduce Revotek’s cell encapsulation technology, or Biosynsphere, for the use in its basic and translational research in stem cell regenerative medicine. On April 22, the instrument (Biosynspherer) and its first batch of reagents and consumables were delivered to the laboratory of West China Hospital of Sichuan University. Revotek’s 3D blood vessel bioprinter is scheduled to be delivered to the hospital laboratory in Q3, 2021.
- April 29: AsiaOne
- April 29: Intellasia
- April 29: Value Buddies
- April 29: Money Compass
- April 29: Finanzen
- April 29: WFMZ-TV
- April 29: PR Newswire Asia